Spero Therapeutics (SPRO) Projected to Post Quarterly Earnings on Thursday

Spero Therapeutics (NASDAQ:SPRO) will likely be posting its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect the company to announce earnings of ($0.47) per share for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

Spero Therapeutics (NASDAQ:SPRO) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01. Spero Therapeutics had a return on equity of 16.17% and a net margin of 24.90%. On average, analysts expect Spero Therapeutics to post ($0.97) EPS for the current fiscal year and ($0.93) EPS for the next fiscal year.

Spero Therapeutics Trading Up 3.9%

NASDAQ SPRO opened at $1.07 on Tuesday. Spero Therapeutics has a 12 month low of $0.96 and a 12 month high of $3.08. The stock has a 50-day simple moving average of $1.15 and a 200 day simple moving average of $1.94. The company has a market capitalization of $62.32 million, a PE ratio of 9.73 and a beta of 1.59.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on SPRO. Compass Point upgraded Spero Therapeutics to a “neutral” rating in a research report on Monday, September 14th. Cantor Fitzgerald began coverage on shares of Spero Therapeutics in a research report on Wednesday, October 28th. They issued an “overweight” rating and a $6.00 price target on the stock. Wall Street Zen downgraded shares of Spero Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 31st. HC Wainwright lifted their price objective on shares of Spero Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a research note on Monday, September 14th. Finally, Weiss Ratings cut shares of Spero Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, October 26th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Spero Therapeutics has a consensus rating of “Hold” and a consensus price target of $6.00.

About Spero Therapeutics

Spero Therapeutics, Inc (NASDAQ:SPRO) is a biopharmaceutical company focused on developing treatments for multidrug-resistant bacterial infections and certain rare diseases. The company’s research programs are designed to address infections for which existing antibiotics may be inadequate, including complicated urinary tract infections and infections caused by difficult-to-treat pathogens.

Spero’s lead product candidate has been tebipenem pivoxil hydrobromide, an orally administered carbapenem antibiotic developed for the treatment of complicated urinary tract infections.